AMED Amedeo Res

RNS No 7605n
CHIROSCIENCE GROUP PLC
1st July 1997
                                                         
             CHIROSCIENCE ANNOUNCES CHANGES
                 TO R&D RESPONSIBILITIES
 
Chiroscience announces today the appointment of Dr Robert
Jackson   as   Executive  Director   for   Research   and
Development  for its Darwin Discovery activities  in  the
UK.   Dr Jackson will be based in Cambridge, UK, and will
report   to   Dr   John  Padfield,  Chief  Executive   of
Chiroscience   Group  plc,  alongside  Dr  David   Galas,
Executive  Director  for Discovery  Research  for  Darwin
Discovery activities in the USA.
 
Dr  Jackson joins Chiroscience from Agouron where he  was
Vice President for Research and Development.  Agouron  is
a  major US biotechnology company with one of the leading
R&D pipelines in the industry.  Its first drug, for which
Dr  Jackson  was  responsible, has  just  been  launched.
Prior  to joining Agouron in 1992, Dr Jackson held senior
industrial  positions in Du Pont Merck and Warner-Lambert
over  a  10 year period and academic positions in Indiana
University, Scripps Clinic and the University  of  London
Institute of Cancer Research.
 
Bob  Jackson  is  54 and was educated  in  Cambridge  and
London  before conducting post-doctoral research at  Yale
University  School  of Medicine.  He is  well  recognised
within   the  cancer  field  and  has  published  widely,
including research on matrix metalloproteinases.
 
Dr  Jackson  will be responsible for all  biological  and
chemical  research and development, technical  operations
and  clinical  development activities  in  Cambridge  and
Stevenage.
 
Dr  Jon  Dickens, who has been responsible for  the  pre-
clinical  research activities in Cambridge, has indicated
his wish to leave Chiroscience to pursue other interests.
He  will  act  as  a consultant to the Group  on  defined
projects.
 
Commenting,   Dr  John  Padfield,  Chief   Executive   of
Chiroscience  said, 'The growth in our  applied  research
programmes,  particularly  in  the  exploitation  of  our
investment in enzyme inhibitors through their development
for  a  number  of  clinical end points,  requires  their
leadership  and co-ordination through one director.   Bob
Jackson's  experience  and  record  make  him  an   ideal
candidate for this role and I am delighted he has  joined
us.   Jon  Dickens has played a key role in  research  in
helping  Chiroscience reach this point.  We wish him  all
success in his future career.'
 
 
For further information please contact:
 
Dr John Padfield, Chief Executive  Matthew Hooper/Sarah Carrell
Chiroscience Group plc             Shandwick Consultants
Tel: 01223 420430                  Tel: 0171 329 0096
 
 
END

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Lug 2023 a Lug 2024